Recurrent Atrial Fibrillation Market Overview Highlighting Major Drivers, Trends, Growth and Demand Report 2020- 2027

April 06 22:00 2021
The revolutions in personalized drug development, potential device technologies in the pipeline, increasing incidence of recurrent AFib coupled with deteriorating lifestyles would augment the prevalence of the disease leading to the growth of the Recurrent Atrial Fibrillation market.

The global Recurrent Atrial Fibrillation Market is expected to reach USD 25.93 Billion by 2027, according to a new report by Emergen Research. The increasing incidence of recurrent atrial fibrillation is majorly associated with recurrent paroxysmal atrial fibrillation patients, with the occurrence of a family history of AFib, high blood pressure, sleep apnea, overuse of stimulants, alcohol consumption, obesity, thyroid disorders, diabetes, lung disease, severe infections, and stress.

Request a sample copy of the report @ https://www.emergenresearch.com/request-sample/71

Key Highlights From The Report

  • In January 2019, Abbott announced the acceptance of the TactiCath Touch Force Ablation Catheter by the FDA. Such winning tactics of leading companies in the market for atrial fibrillation products are often adopted by national and local companies.
  • The prevalence of AFib ranges between 2.7 million and 6.1 million in the U.S. alone and is estimated to reach 12.1 million by the year 2030, according to the statistics of the Center for Disease Control. Similar incidence rates are observed in other regions as well, indicating potential growth in the target industry.
  • Atrial fibrillation diagnosis includes screening as regular care in elderly patients and patients with other risk factors. Diagnostic testing also includes an ECG or EKG heart’s electrical activity. The presence of advanced software based ECG monitoring devices would improve the quality of treatment for recurrent atrial fibrillation patients.
  • Key participants contributing significant market shares in the industry growth includes Johnson & Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.

Emergen Research have segmented the global Recurrent Atrial Fibrillation Market on the basis of product, application, end-uses, and region:

  • Product Outlook (Revenue, USD Billion; 2017-2027)
    • Device
    • Surgical Devices
      1. Maze Surgery
      2. Catheter Ablation
      3. Radiofrequency Catheter Ablation
        1. Conventional RF Ablation Catheters
        2. Irrigated-tip RF Ablation Catheters
      4. Cryoablation
      5. Microwave Based Catheter Ablation
      6. Laser Based Catheter Ablation
      7. Navigational Advanced Mapping Accessories
    • Non-Surgical Devices
      1. Electric Cardioversion
      2. EP Ablation Catheters
      3. EP Diagnostic Catheter
      4. Conventional Diagnostic Catheters
        1. Fixed Diagnostic Catheters
        2. Steerable Diagnostic Catheters
      5. Advanced Diagnostic Catheters
      6. Mapping and Recording Systems
      7. Cardiac Monitors or Loop Recorders
      8. Access Devices
      9. Left Atrial Appendage and Closure Devices
      10. Intracardiac Echocardiography (ICE) Systems
    • Drugs
      1. Dabigatran (Pradaxa)
      2. Rivaroxaban (Xarelto)
      3. Apixaban (Eliquis)
      4. Edoxaban (Savaysa)
      5. Warfarin (Coumadin)
      6. Others
    • Application Outlook (Revenue, USD Billion; 2017-2027)
      • EP Ablation
      • Diagnostic
      • Surgical Cardiac
    • End Users Outlook (Revenue, USD Billion; 2017-2027)
      • Hospitals
      • Cardiac Centers
      • Ambulatory Care Centers

Regional Bifurcation:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/71

Key Factors influencing market remuneration:

  • The global Recurrent Atrial Fibrillation market report includes a detailed study of the product spectrum of the market and further describes the different product types, including One-sided, Two-sided, and Others.
  • The report zeroes in on the overall market dynamics and presents information with regard to the producers and distributors, manufacturing cost structure, and downstream buyers.
  • Details pertaining to the expected growth rate, industry share, revenue accumulated, and product segmentationare depicted in this report.
  • The application landscape of the global Recurrent Atrial Fibrillation market can be categorized into For Human, For Animals, and Others.
  • The study further examines the industry share and product demand of each application, coupled withthe predicted growth patterns of the various application segments.
  • Other vital factors, such as market concentration ratioand raw material processing rate, have also been covered under the latest study.

Table of Content

Chapter 1. Methodology & Sources
    1.1. Market Definition
    1.2. Research Scope
    1.3. Methodology
    1.4. Research Sources
          1.4.1. Primary
          1.4.2. Secondary
          1.4.3. Paid Sources
    1.5. Market Estimation Technique
Chapter 2. Executive Summary
    2.1. Summary Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Recurrent Atrial Fibrillation Market Segmentation & Impact Analysis
    4.1. Recurrent Atrial Fibrillation Market Material Segmentation Analysis
    4.2. Industrial Outlook
          4.2.1. Market indicators analysis
          4.2.2. Market drivers analysis
                    4.2.2.1. Rising incidence of heart diseases
                    4.2.2.2. Growing demand of the minimally invasive procedures
                    4.2.2.3. Technological advancement
    4.3. Market restraints analysis
                    4.3.1.1. High Cost of devices
    4.4. Technological Insights
    4.5. Regulatory Framework
    4.6. Porter’s Five Forces Analysis
    4.7. Competitive Metric Space Analysis
    4.8. Price trend Analysis
    4.9. Covid-19 Impact Analysis

Chapter 5. Recurrent Atrial Fibrillation Market By Product Insights & Trends, Revenue (USD Million)
    5.1. Product Dynamics & Market Share, 2019 & 2027
          5.1.1. Device
                    5.1.1.1. Surgical Devices
                                 5.1.1.1.1. Maze Surgery
                                 5.1.1.1.2. Catheter Ablation
                                 5.1.1.1.3. Radiofrequency Catheter Ablation
                                                5.1.1.1.3.1. Conventional RF Ablation Catheters
                                                5.1.1.1.3.2. Irrigated-tip RF Ablation Catheters
                                 5.1.1.1.4. Cryoablation
                                 5.1.1.1.5. Microwave Based Catheter Ablation
                                 5.1.1.1.6. Laser Based Catheter Ablation
                                 5.1.1.1.7. Navigational Advanced Mapping Accessories
                    5.1.1.2. Non-Surgical Devices
                                 5.1.1.2.1. Electric Cardioversion
                                 5.1.1.2.2. EP Ablation Catheters
                                 5.1.1.2.3. EP Diagnostic Catheter
                                 5.1.1.2.4. Conventional Diagnostic Catheters
                                                5.1.1.2.4.1. Fixed Diagnostic Catheters
                                                5.1.1.2.4.2. Steerable Diagnostic Catheters
                                 5.1.1.2.5. Advanced Diagnostic Catheters
                                 5.1.1.2.6. Mapping and Recording Systems
                                 5.1.1.2.7. Cardiac Monitors or Loop Recorders
                                 5.1.1.2.8. Access Devices
                                 5.1.1.2.9. Left Atrial Appendage and Closure Devices
                                 5.1.1.2.10. Intracardiac Echocardiography (ICE) Systems
          5.1.2. Drugs
                    5.1.2.1. Dabigatran (Pradaxa)
                    5.1.2.2. Rivaroxaban (Xarelto)
                    5.1.2.3. Apixaban (Eliquis)
                    5.1.2.4. Edoxaban (Savaysa)
                    5.1.2.5. Warfarin (Coumadin)
                    5.1.2.6. Others

CONTINUED…!!

To know more about the report, visit @ https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market

Thank you for reading our report. To know more about the report, please connect with us, and our team will ensure the report is customized to meet your requirements.

Media Contact
Company Name: Emergen Research
Contact Person: Eric Lee
Email: Send Email
Phone: +1 (604) 757-9756
Address:14671 110 Avenue Surrey, British Columbia, V3R2A9
City: Surrey
State: British Columbia
Country: Canada
Website: https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market

view more articles

About Article Author